Nrtx-1001
Epilepsy, Temporal Lobe
Neurona TherapeuticsCell therapyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Epilepsy, Temporal Lobe cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NALUZOTAN National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | CCC |
Ferumoxytol University of Alberta | Phase 2 | CCC |
aav9-hsyn1-migrik2 UniQure Biopharma B.V. | Phase 1/2 | CCC |
Ux-Gip001 Second Affiliated Hospital, School of Medicine, Zhejiang University | Early Phase 1 | C |
Florbetaben University of Minnesota | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →